X4 Pharmaceuticals (XFOR) Profit After Tax Growth (1y) (2018 - 2026)
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Profit After Tax Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -19.06% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -108.47% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -90.18% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 151.28% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 44.59% |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | 37.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37.23% |
| Mar 31, 2026 | -7,277.66% |
| Dec 31, 2025 | 39.98% |
| Sep 30, 2025 | 18.75% |
| Jun 30, 2025 | -128.34% |
| Mar 31, 2025 | 100.54% |
| Dec 31, 2024 | -108.16% |
| Sep 30, 2024 | -1,492.02% |
| Jun 30, 2024 | 263.04% |
| Mar 31, 2024 | -115.51% |
| Dec 31, 2023 | 34.27% |
| Sep 30, 2023 | 89.32% |
| Jun 30, 2023 | -162.64% |
| Mar 31, 2023 | -9.36% |
| Dec 31, 2022 | 3.65% |
| Sep 30, 2022 | -6.99% |
| Jun 30, 2022 | -8.02% |
| Mar 31, 2022 | -17.61% |
| Dec 31, 2021 | -64.17% |
| Sep 30, 2021 | -15.62% |